Published in:
01-10-2017 | Epidemiology
Oncologists’ influence on receipt of adjuvant chemotherapy: does it matter whom you see for treatment of curable breast cancer?
Published in: Breast Cancer Research and Treatment | Issue 3/2017
Login to get accessAbstract
Purpose
We know little about whether it matters which oncologist a breast cancer patient sees with regard to receipt of chemotherapy. We examined oncologists’ influence on use of recurrence score (RS) testing and chemotherapy in the community.
Methods
We identified 7810 women with stages 0-II breast cancer treated in 2013-15 through the SEER registries of Georgia and Los Angeles County. Surveys were sent 2 months post-surgery, (70% response rate, n = 5080). Patients identified their oncologists (n = 504) of whom 304 responded to surveys (60%). We conducted multi-level analyses on patients with ER-positive HER2-negative invasive disease (N = 2973) to examine oncologists’ influence on variation in RS testing and chemotherapy receipt, using patient and oncologist survey responses merged to SEER data.
Results
Half of patients (52.8%) received RS testing and 27.7% chemotherapy. One-third (35.9%) of oncologists treated >50 new breast cancer patients annually; mean years in practice was 15.8. Oncologists explained 17% of the variation in RS testing but little of the variation in chemotherapy receipt (3%) controlling for clinical factors. Patients seeing an oncologist who was one standard deviation above the mean use of RS testing had over two-times higher odds of receiving RS (2.47, 95% CI 1.47–4.15), but a parallel estimate of the association of oncologist with the odds of receiving chemotherapy was much smaller (1.39, CI 1.03–1.88).
Conclusions
Clinical algorithms have markedly reduced variation in chemotherapy use across oncologists. Oncologists’ large influence on variation in RS use suggests that they variably seek tumor profiling to inform treatment decisions.